Literature DB >> 33823785

Reversible cerebral vasoconstriction syndrome (RCVS): an interesting case report.

Mansoureh Togha1,2, Mahsa Babaei3, Parvin Ganji Ghelichi4.   

Abstract

BACKGROUND: Reversible Cerebral Vasoconstriction Syndrome is a condition of transient cerebral vascular spasms, which usually presents with recurrent thunderclap headaches and recovers within 3 months. Several probable triggers and underlying factors, such as sex hormones, vasoactive drugs, head trauma or surgery, and tumors, have been implicated. CASE
PRESENTATION: In this paper, we present a 53-year-old woman with thunderclap headaches and normal lab tests who was radio-clinically diagnosed with reversible cerebral vasoconstriction syndrome and treated accordingly. Then, she experienced the recurrence of RCVS after about 2 years and headaches after 1 year in association with high blood pressure, high blood sugar, hypothyroidism, hyperlipidemia, and a urine metanephrine level of 5 times higher than the normal limit, suggesting a diagnosis of pheochromocytoma. After confirmation of the diagnosis with further imaging studies, surgical removal of the tumor resolved all the signs and symptoms.
CONCLUSION: Often underdiagnosed, pheochromocytoma could be an important condition associated with RCVS. It is important for clinicians to bear this diagnosis in mind while dealing with similar cases of recurrent thunderclap headaches.

Entities:  

Keywords:  Pheochromocytoma; Reversible cerebral vasoconstriction syndrome; Thunder-clap headache

Mesh:

Year:  2021        PMID: 33823785     DOI: 10.1186/s10194-021-01225-7

Source DB:  PubMed          Journal:  J Headache Pain        ISSN: 1129-2369            Impact factor:   7.277


  20 in total

1.  Recurrence of reversible cerebral vasoconstriction syndrome: a long-term follow-up study.

Authors:  Shih-Pin Chen; Jong-Ling Fuh; Jiing-Feng Lirng; Yen-Feng Wang; Shuu-Jiun Wang
Journal:  Neurology       Date:  2015-03-18       Impact factor: 9.910

2.  Current management of pheochromocytoma.

Authors:  W H Remine; G C Chong; J A Van Heerden; S G Sheps; E G Harrison
Journal:  Ann Surg       Date:  1974-05       Impact factor: 12.969

Review 3.  Clinical evaluation and treatment of phaeochromocytoma.

Authors:  Andrew S Davison; Danielle M Jones; Stuart Ruthven; Timothy Helliwell; Susannah L Shore
Journal:  Ann Clin Biochem       Date:  2017-11-08       Impact factor: 2.057

Review 4.  Reversible cerebral vasoconstriction syndrome: current and future perspectives.

Authors:  Shih-Pin Chen; Jong-Ling Fuh; Shuu-Jiun Wang
Journal:  Expert Rev Neurother       Date:  2011-09       Impact factor: 4.618

Review 5.  The Typical Thunderclap Headache of Reversible Cerebral Vasoconstriction Syndrome and its Various Triggers.

Authors:  Anne Ducros; Valérie Wolff
Journal:  Headache       Date:  2016-03-26       Impact factor: 5.887

6.  Pheochromocytoma: study of 50 cases.

Authors:  A M Lucon; M A Pereira; B B Mendonça; A Halpern; B L Wajchenbeg; S Arap
Journal:  J Urol       Date:  1997-04       Impact factor: 7.450

7.  Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine.

Authors:  Graeme Eisenhofer; David S Goldstein; Patricia Sullivan; Gyorgy Csako; Frederieke M Brouwers; Edwin W Lai; Karen T Adams; Karel Pacak
Journal:  J Clin Endocrinol Metab       Date:  2005-01-11       Impact factor: 5.958

Review 8.  Pheochromocytoma, diagnosis and treatment: Review of the literature.

Authors:  F A Farrugia; G Martikos; P Tzanetis; A Charalampopoulos; E Misiakos; N Zavras; D Sotiropoulos
Journal:  Endocr Regul       Date:  2017-07-01

9.  The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients.

Authors:  Anne Ducros; Monique Boukobza; Raphaël Porcher; Mariana Sarov; Dominique Valade; Marie-Germaine Bousser
Journal:  Brain       Date:  2007-11-19       Impact factor: 13.501

10.  Pheochromocytoma in children and adolescents.

Authors:  H K Ganesh; Shrikrishna V Acharya; Joe Goerge; Tushar R Bandgar; Padma S Menon; Nalini S Shah
Journal:  Indian J Pediatr       Date:  2010-01-14       Impact factor: 1.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.